title: Generic piperacillin/tazobactam is not associated with galactomannan false-positivity in adult patients with cancer: a case-control study.
abstract: Recent products of piperacillin/tazobactam (PTZ) from the original manufacturer, previously considered a major cause of galactomannan (GM) false-positivity, are reported not to be related to it. However, data regarding generic PTZ are limited and controversial. To evaluate the effect of generic PTZ on GM false-positivity in Korea, we performed a case-control study in adult patients with cancer. A case-control study was designed. Electronic medical records of cancer patients who were admitted and tested for serum GM between March and June 2014 at a tertiary care university hospital were reviewed. During the study period, a single generic PTZ (C manufacturer, Korea) was used. Patients who received PTZ within 24 h prior to serum GM testing were enrolled. Age- and GM test date-matched non-PTZ patients were selected as controls. A total of 110 patients received PTZ within 24 h prior to serum GM testing during the study period. The GM optical density index (ODI) of the PTZ group did not vary significantly from that of the control group (p = 0.251). The percentage of false-positive patients in the PTZ group was also similar to that of the control group (p = 0.538). There was no statistical relationship between GM ODI titer and time interval from PTZ administration (p = 0.095) or cumulative PTZ dose (p = 0.416). In a case-control study that evaluated 220 patients, a generic PTZ in Korea was not related to GM false-positivity.
authors.affiliation: Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 135-710, Republic of Korea.
authors.forename: J-H
authors.initials: JH
authors.lastname: Ko
authors.forename: K R
authors.initials: KR
authors.lastname: Peck
authors.forename: W J
authors.initials: WJ
authors.lastname: Lee
authors.forename: J Y
authors.initials: JY
authors.lastname: Lee
authors.forename: S Y
authors.initials: SY
authors.lastname: Cho
authors.forename: Y E
authors.initials: YE
authors.lastname: Ha
authors.forename: C-I
authors.initials: CI
authors.lastname: Kang
authors.forename: D R
authors.initials: DR
authors.lastname: Chung
authors.forename: C W
authors.initials: CW
authors.lastname: Jung
authors.forename: E-S
authors.initials: ES
authors.lastname: Kang
authors.forename: J-H
authors.initials: JH
authors.lastname: Song
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000946:Antigens, Fungal / Q000097:blood; D001228:Aspergillosis / Q000097:blood / Q000209:etiology; D016022:Case-Control Studies; D005189:False Positive Reactions; D005260:Female; D005690:Galactose / Q000031:analogs & derivatives; D006801:Humans; D008297:Male; D008351:Mannans / Q000097:blood*; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood* / Q000150:complications; D010397:Penicillanic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D010878:Piperacillin / Q000008:administration & dosage / Q000009:adverse effects*; D012189:Retrospective Studies; D000078142:Tazobactam; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D000946:Antigens, Fungal; D008351:Mannans; C012990:galactomannan; D010397:Penicillanic Acid; D000078142:Tazobactam; D010878:Piperacillin; D005690:Galactose